

ERRATUM

Erratum to: Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes

Sanjay Kalra

Published online: March 8, 2017

© The Author(s) 2017. This article is published with open access at Springerlink.com

Erratum to: Diabetes Ther
DOI 10.1007/s13300-017-0235-x

Dr Kalra's commentary was intended to be a preliminary, personal response to the DEVOTE trial results as reported to the press. We apologise if it was not made sufficiently clear in the article that the results of the DEVOTE trial remain to be published in full, and have not yet therefore undergone scientific review.

In addition, Table 1 should include all the four arms of the ORIGIN trial: insulin glargine + omega-3 polyunsaturated fatty acids; insulin glargine + placebo; standard care + omega-3 polyunsaturated fatty acids; and placebo comparator: standard care + placebo.

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The online version of the original article can be found under doi:[10.1007/s13300-017-0235-x](https://doi.org/10.1007/s13300-017-0235-x).

S. Kalra (✉)
Department of Endocrinology, Bharti Hospital,
Karnal, India
e-mail: brideknl@gmail.com